Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 25 March

Grady Wulff
March 25, 2024

Weekly Wrap 22 March

Sophia Mavridis
March 22, 2024

Morning Bell 22 March

Sam Kanaan
March 22, 2024

Market Insights: As Good as Gold

Grady Wulff
March 21, 2024

Morning Bell 21 March

Sophia Mavridis
March 21, 2024

Morning Bell 20 March

Sam Kanaan
March 20, 2024

Morning Bell 19 March

Sam Kanaan
March 19, 2024

Morning Bell 18 March

Sophia Mavridis
March 18, 2024

Weekly Wrap 15 March

Grady Wulff
March 15, 2024

Morning Bell 15 March

Sam Kanaan
March 15, 2024

Morning Bell 14 March

Sophia Mavridis
March 14, 2024

Morning Bell 13 March

Sam Kanaan
March 13, 2024